Reproductive · Gynecology
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Premature ovarian insufficiency is defined as hypergonadotropic hypogonadism occurring before the age of 40 years.
The hallmark laboratory finding is an elevated serum FSH level (menopausal range, e.g. >25 IU/L per current ESHRE criteria; >40 IU/L by older definitions) on a single occasion, together with at least 4 months of amenorrhea or irregular cycles; repeat FSH after 4-6 weeks only if the diagnosis is uncertain.
Patients typically present with secondary amenorrhea, vasomotor symptoms (hot flashes), and genitourinary syndrome of menopause due to estrogen deficiency.
Karyotype analysis is recommended for all patients with non-iatrogenic POI (ESHRE 2024) to rule out Turner syndrome (45,X); separate FMR1 premutation testing is also recommended to evaluate for Fragile X-associated primary ovarian insufficiency.
The majority of premature ovarian insufficiency is idiopathic; among identifiable causes, genetic (Turner syndrome, FMR1 premutation), iatrogenic (chemotherapy/radiation), and autoimmune oophoritis (associated with Addison's disease or thyroiditis) are leading etiologies.
Hormone replacement therapy (HRT) is the standard of care to prevent osteoporosis and cardiovascular disease until the average age of natural menopause.
Patients with premature ovarian insufficiency have a 5-10% chance of spontaneous conception, making contraception necessary if pregnancy is not desired.
Vignette unlocked
A 32-year-old woman presents to the clinic complaining of 8 months of amenorrhea and frequent night sweats. She reports a history of regular menses until last year and denies any recent weight loss, excessive exercise, or medication use. Physical examination reveals atrophic vaginal mucosa with normal pubic and axillary hair. Laboratory evaluation shows a markedly elevated serum FSH and a low serum estradiol level. A pregnancy test is negative.
What is the most appropriate next step in the management of this patient?
Karyotype analysis
The patient meets the criteria for premature ovarian insufficiency; karyotype analysis is recommended (ESHRE 2024) to rule out Turner syndrome and X-chromosome mosaicism; FMR1 premutation testing is a separate molecular assay that should be sent alongside the karyotype.
Full handout
High yield triage
Etiology / Epidemiology
Defined as hypergonadotropic hypogonadism before age 40. Most cases are idiopathic; genetic (Turner syndrome, FMR1 premutation), iatrogenic, and autoimmune causes are the leading identifiable etiologies.
Clinical Manifestations
Presents as secondary amenorrhea with vasomotor symptoms (hot flashes, night sweats) and vaginal dryness.
Diagnosis
FSH levels in the menopausal range (>25 IU/L per current ESHRE criteria; older threshold >40 IU/L) on a single occasion, together with at least 4 months of amenorrhea or irregular cycles, confirm the diagnosis; repeat FSH after 4-6 weeks only if uncertain.
Treatment
Estrogen replacement therapy (with progestin if uterus present) is the standard to prevent bone loss.
Prognosis
High risk of osteoporosis and cardiovascular disease; warrants long-term DEXA scan monitoring.
Full handout
Epidemiology & Etiology
Affects about 1% (older studies) to 3.5% (recent studies, per ESHRE 2024) of women under 40. Etiologies include autoimmune oophoritis, iatrogenic causes (chemotherapy/radiation), and genetic factors like Fragile X premutation. Routinely screen for Turner syndrome (45,X) in primary amenorrhea cases.
Pertinent Anatomy
The ovaries undergo premature follicular depletion or dysfunction. Loss of ovarian feedback leads to a compensatory rise in pituitary gonadotropins.
Pathophysiology
Follicular exhaustion or resistance to gonadotropins results in hypoestrogenism. The loss of negative feedback causes a massive rise in FSH and LH. This hormonal milieu mimics natural menopause but occurs prematurely.
Clinical Manifestations
Patients present with secondary amenorrhea, infertility, and symptoms of estrogen deficiency. Look for genitourinary syndrome of menopause and dyspareunia. Red flag: Rule out pregnancy with a hCG test before diagnosing.
Diagnosis
Diagnosis is confirmed by elevated FSH in the menopausal range (>25 IU/L per ESHRE; older threshold >40 IU/L) on a single occasion in a woman with at least 4 months of amenorrhea or irregular cycles, repeated after 4-6 weeks only if the diagnosis is uncertain. Perform a karyotype to rule out Y-chromosome material, which carries a high risk of gonadoblastoma.
Treatment
Hormone replacement therapy (HRT) is the first-line treatment to mitigate menopausal symptoms and bone loss. Contraindications include history of breast cancer, undiagnosed vaginal bleeding, or active thromboembolic disease. Progestin should be added if the patient has a uterus to prevent endometrial hyperplasia.
Prognosis
Patients face significant long-term risks of osteoporosis and early cardiovascular disease. DEXA is recommended at diagnosis and periodically thereafter to monitor bone mineral density.
Differential Diagnosis
Pregnancy: ruled out by serum hCG
Hypothalamic amenorrhea: low/normal FSH and LH
Hyperprolactinemia: elevated prolactin levels
Thyroid disease: abnormal TSH/T4
PCOS: elevated androgens and normal/low FSH